Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). (Q45835594)

16 December 2017

title

Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). (English)

1 reference

16 December 2017

Heart failure with preserved ejection fraction

0 references

1 reference

1 reference

1 reference

1 reference

Kazuhiro Yamamoto

1

1 reference

16 December 2017

Hideki Origasa

series ordinal

2

1 reference

16 December 2017

Masatsugu Hori

series ordinal

3

1 reference

16 December 2017

J-DHF Investigators

series ordinal

4

1 reference

16 December 2017

language of work or name

1 reference

14 September 2012

1 reference

16 December 2017

European Journal of Heart Failure

published in

1 reference

16 December 2017

volume

15

1 reference

16 December 2017

page(s)

110-118

1 reference

16 December 2017

issue

1

1 reference

16 December 2017

Epidemiology and clinical course of heart failure with preserved ejection fraction

cites work

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS141

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS141

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS141

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS141

Irbesartan in patients with heart failure and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS141

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS141

Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS141

Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS141

Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS141

Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS141

Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS141

Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Fail

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS141

Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS141

The Natural History of Congestive Heart Failure: The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS141

Long-term beta-blocker therapy improves diastolic function even without the therapeutic effect on systolic function in patients with reduced ejection fraction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS141

Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS141

Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS141

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS141

Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS141

Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS141

How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS141

Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS141

Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS141

Dose-dependent prognostic effect of carvedilol in patients with chronic heart failure--special reference to transcardiac [corrected] gradient of norepinephrine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS141

21 January 2018

Identifiers

DOI

10.1093/EURJHF/HFS141

1 reference

16 December 2017

release_gcdjiddhjrcnjfsnif5q2sshnq

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gcdjiddhjrcnjfsnif5q2sshnq

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

22983988

1 reference

16 December 2017